Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Mesenchymal stem/stromal cells genetically engineered to produce vascular endothelial growth factor for revascularization in wound healing and ischemic conditions.

Fierro FA, Magner N, Beegle J, Dahlenburg H, Logan White J, Zhou P, Pepper K, Fury B, Coleal-Bergum DP, Bauer G, Gruenloh W, Annett G, Pifer C, Nolta JA.

Transfusion. 2019 Feb;59(S1):893-897. doi: 10.1111/trf.14914. Epub 2018 Nov 1.

PMID:
30383901
2.

Preclinical evaluation of mesenchymal stem cells overexpressing VEGF to treat critical limb ischemia.

Beegle JR, Magner NL, Kalomoiris S, Harding A, Zhou P, Nacey C, White JL, Pepper K, Gruenloh W, Annett G, Nolta JA, Fierro FA.

Mol Ther Methods Clin Dev. 2016 Aug 24;3:16053. doi: 10.1038/mtm.2016.53. eCollection 2016.

3.

Intravitreal Administration of Human Bone Marrow CD34+ Stem Cells in a Murine Model of Retinal Degeneration.

Moisseiev E, Smit-McBride Z, Oltjen S, Zhang P, Zawadzki RJ, Motta M, Murphy CJ, Cary W, Annett G, Nolta JA, Park SS.

Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4125-35. doi: 10.1167/iovs.16-19252.

PMID:
27537262
4.

Clinical trial perspective for adult and juvenile Huntington's disease using genetically-engineered mesenchymal stem cells.

Deng P, Torrest A, Pollock K, Dahlenburg H, Annett G, Nolta JA, Fink KD.

Neural Regen Res. 2016 May;11(5):702-5. doi: 10.4103/1673-5374.182682. Review.

5.

Engineered BDNF producing cells as a potential treatment for neurologic disease.

Deng P, Anderson JD, Yu AS, Annett G, Fink KD, Nolta JA.

Expert Opin Biol Ther. 2016 Aug;16(8):1025-33. doi: 10.1080/14712598.2016.1183641. Epub 2016 May 21. Review.

6.

Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts.

Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A, Kalomoiris S, Cary W, Anderson JD, Gruenloh W, Duffy A, Tempkin T, Annett G, Wheelock V, Segal DJ, Nolta JA.

Cell Transplant. 2016;25(4):677-86. doi: 10.3727/096368916X690863. Epub 2016 Feb 4.

7.

Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models.

Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, Annett G, Torrest A, Deng P, Gutierrez J, Nacey C, Pepper K, Kalomoiris S, D Anderson J, McGee J, Gruenloh W, Fury B, Bauer G, Duffy A, Tempkin T, Wheelock V, Nolta JA.

Mol Ther. 2016 May;24(5):965-77. doi: 10.1038/mt.2016.12. Epub 2016 Jan 14.

8.

Developing stem cell therapies for juvenile and adult-onset Huntington's disease.

Fink KD, Deng P, Torrest A, Stewart H, Pollock K, Gruenloh W, Annett G, Tempkin T, Wheelock V, Nolta JA.

Regen Med. 2015;10(5):623-46. doi: 10.2217/rme.15.25. Review.

9.

Modeling children's white matter volume intelligence and academic achievement in response to CNS-directed therapy.

Annett RD, Annett GE.

Pediatr Blood Cancer. 2014 Jun;61(6):960-1. doi: 10.1002/pbc.24998. Epub 2014 Feb 20. No abstract available.

PMID:
24623681
10.

Mesenchymal stem cells for trinucleotide repeat disorders.

Annett G, Bauer G, Nolta JA.

Methods Mol Biol. 2013;1010:79-91. doi: 10.1007/978-1-62703-411-1_6.

11.

Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease.

Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J, Stewart H, McGee J, Bauer G, Kim HS, Tempkin T, Wheelock V, Annett G, Dunbar G, Nolta JA.

Mol Neurobiol. 2012 Feb;45(1):87-98. doi: 10.1007/s12035-011-8219-8. Epub 2011 Dec 9. Review.

12.

Mesenchymal stem cells for the treatment of neurodegenerative disease.

Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA.

Regen Med. 2010 Nov;5(6):933-46. doi: 10.2217/rme.10.72. Review.

13.

Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.

Meyerrose T, Olson S, Pontow S, Kalomoiris S, Jung Y, Annett G, Bauer G, Nolta JA.

Adv Drug Deliv Rev. 2010 Sep 30;62(12):1167-74. doi: 10.1016/j.addr.2010.09.013. Epub 2010 Oct 13. Review.

14.

Contribution of human hematopoietic stem cells to liver repair.

Zhou P, Wirthlin L, McGee J, Annett G, Nolta J.

Semin Immunopathol. 2009 Sep;31(3):411-9. doi: 10.1007/s00281-009-0166-3. Epub 2009 Jun 17. Review.

15.

T cell depleted haploidentical bone marrow transplantation for the treatment of children with severe combined immunodeficiency.

Smogorzewska EM, Brooks J, Annett G, Kapoor N, Crooks GM, Kohn DB, Parkman R, Weinberg KI.

Arch Immunol Ther Exp (Warsz). 2000;48(2):111-8.

PMID:
10807052
16.

Localization of a gene for Duane retraction syndrome to chromosome 2q31.

Appukuttan B, Gillanders E, Juo SH, Freas-Lutz D, Ott S, Sood R, Van Auken A, Bailey-Wilson J, Wang X, Patel RJ, Robbins CM, Chung M, Annett G, Weinberg K, Borchert MS, Trent JM, Brownstein MJ, Stout JT.

Am J Hum Genet. 1999 Dec;65(6):1639-46.

17.

Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count.

Bolotin E, Annett G, Parkman R, Weinberg K.

Bone Marrow Transplant. 1999 Apr;23(8):783-8.

18.

T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.

Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R.

Nat Med. 1998 Jul;4(7):775-80.

19.

The effect of thymic function on immunocompetence following bone marrow transplantation.

Weinberg K, Annett G, Kashyap A, Lenarsky C, Forman SJ, Parkman R.

Biol Blood Marrow Transplant. 1995 Nov;1(1):18-23.

PMID:
9118285
20.

Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.

Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, el-Khoureiy A, et al.

Nat Med. 1995 Oct;1(10):1017-23.

21.

MDR1 gene expression in brain of patients with medically intractable epilepsy.

Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C.

Epilepsia. 1995 Jan;36(1):1-6.

PMID:
8001500
22.
23.

Correction of antigen-specific T-lymphocyte function by recombinant cytokines in children infected with human immunodeficiency virus type 1.

Petersen JM, Weinberg KI, Annett G, Church J, Gomperts E, Parkman R.

J Pediatr. 1992 Oct;121(4):565-8.

PMID:
1357123
24.

Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission.

Lenarsky C, Weinberg K, Petersen J, Nolta J, Brooks J, Annett G, Kohn D, Parkman R.

Bone Marrow Transplant. 1990 Dec;6(6):425-9.

PMID:
2097012

Supplemental Content

Loading ...
Support Center